Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YG1699 vs Dapagliflozin in T1DM
NCT04956263Phase 2Completed
- Sponsor
- Youngene Therapeutics
- Start
- Jun 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YG1699 in type 1 diabetes mellitus (T1D), sponsored by Youngene Therapeutics. Started Jun 2021; status: completed.
02
Drugs
YG1699
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04956263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04956263.